ArticleJournal, genetic engineering & biotechnology2026
Structure-based identification of small-molecule stabilizers targeting mutant TP53 (Y220C) in breast cancer: a pharmacophore modeling, molecular docking and dynamics study.
Article in Journal, genetic engineering & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMutations in TP53, particularly the Y220C variant, destabilize the protein and impair tumor-suppressor function, driving breast cancer progression. Restoring the structural integrity of TP53 Y220C using small-molecule stabilizers represents a potential therapeutic strategy.
methodsPharmacophore modeling based on the co-crystal ligand binding site guided screening of a ligand library using the Pharmit platform. Molecular docking, ADME, and toxicity predictions filtered drug-like and safe candidates. Molecular dynamics simulations (MDS) and per-residue MM/PBSA analyses assessed binding stability, structural fluctuations, and energetic contributions.
resultsTP53 Y220C was found to be highly expressed in breast cancer. Pharmacophore-guided virtual screening and molecular docking identified several promising compounds with favorable drug-likeness and safety profiles. Among these, three ligands, including CPD0001, CPD0136, and CPD0330, demonstrated stable binding and favorable interactions with the Y220C cavity. Molecular dynamics analyses revealed that CPD0001 and CPD0136 maintained superior structural stability, reduced conformational fluctuations, compact cavity organization, and coordinated residue motions throughout the simulation period, closely resembling the co-crystal ligand. In contrast, CPD0330 demonstrated moderate stabilization with comparatively higher flexibility. MM/PBSA and per-residue energy decomposition analyses further supported the strong binding affinity and stabilizing potential of CPD0001 and CPD0136. CPD0330 showed moderate stabilization comparable to co-crystal ligands.
conclusionsOverall, CPD0001 and CPD0136 emerged as promising small-molecule stabilizers capable of reinforcing the TP53 Y220C mutant cavity and maintaining structural stability comparable to the co-crystal ligand. These findings highlight their potential as lead candidates for the development of targeted therapeutics against TP53 Y220C-driven breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.